PTC Therapeutics, Inc. (PTCT) stock
PTCTNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Oct 29, 2026Score 5/3031% above fair value
$63.49+0.13 (+0.21%)
Close on Nov 13, 2026Market cap $5.30BP/E –Yield –
PTC Therapeutics enterprise value
Enterprise value is market cap plus debt, minus cash: the value of the whole business to all its investors.
PTC Therapeutics's enterprise value was $3.77B on Nov 11, 2026, against $5.46B a year earlier. Over the last 5 years it ranged from $1.53B to $5.46B, with a median of $2.94B.
Enterprise Value at the end of each year
| Period | Period end | Value | Change |
|---|---|---|---|
| 2026 | Nov 11, 2026 | $3.77B | -19.0% |
| 2025 | Dec 31, 2025 | $4.66B | +70.5% |
| 2024 | Dec 31, 2024 | $2.73B | +16.6% |
| 2023 | Dec 29, 2023 | $2.34B | -13.9% |
| 2022 | Dec 30, 2022 | $2.72B | +14.8% |
| 2021 | Dec 31, 2021 | $2.37B | -28.0% |
| 2020 | Dec 31, 2020 | $3.29B | +28.9% |
| 2019 | Dec 31, 2019 | $2.55B | +56.5% |
| 2018 | Dec 31, 2018 | $1.63B | +145.3% |
| 2017 | Dec 29, 2017 | $665.39M | +201.1% |
| 2016 | Dec 30, 2016 | $220.97M | -69.6% |
| 2015 | Dec 31, 2015 | $727.33M | -44.5% |
| 2014 | Dec 31, 2014 | $1.31B | +431.3% |
| 2013 | Dec 31, 2013 | $246.80M | – |
See a number that looks wrong?